Agilent Leverages NVIDIA and AWS Technology to Improve Analysis Speeds of Genomics Bioinformatics Pipelines
Agilent Technologies (NYSE: A) has announced the integration of its Alissa data analysis platform with NVIDIA's Clara Parabricks and Amazon EC2 G5g instances. This collaboration aims to enhance genomic data processing speeds, improving workflows for clinical labs and researchers. The integration supports Agilent's SureSelect NGS assays, allowing for cost-effective, targeted sequencing. The partnership with AWS focuses on leveraging global data security and cloud capabilities, enhancing efficiency and reducing analysis turnaround times for genomic experiments.
- Integration with NVIDIA Clara Parabricks and AWS enhances genomic data processing speeds.
- Offers streamlined workflow solutions for SureSelect NGS assays, increasing efficiency.
- Collaboration enhances global data security and cloud capabilities.
- None.
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
This collaboration enables Agilent to offer streamlined workflow solutions for its SureSelect family of next-generation sequencing (NGS) assays comprising a wide range of custom and catalog panels, including SureSelect Human Exome reagents. The integration of NVIDIA Clara Parabricks platform with the Alissa secondary analysis pipelines enables clinical labs and researchers to benefit from fast panel-specific data analysis solutions in a secure and user-friendly cloud software environment.
“Agilent’s SureSelect panels are widely utilized to enrich samples for specific genes of interest, enabling cost-effective targeted sequencing. We’re now able to leverage our bioinformatics expertise, in combination with NVIDIA’s compute expertise, to offer our customers optimized analysis solutions through a combination of Agilent’s optimized variant calling algorithms and NVIDIA’s accelerated compute capabilities,” said
“We’re also excited to extend our collaboration with AWS to further leverage its data security capabilities and global reach, so we can offer cloud-based analysis capabilities to customers on a global basis,” Meldrum added.
“As the scale and scope of genomics experiments accelerates, reducing analysis turnaround times is more important than ever,” said
“Working with Agilent and NVIDIA, we are giving genomics customers worldwide the ability to take advantage of and innovation with AWS’s secure and transformative cloud computing capabilities that offer the best cost and performance globally. Running genomics workloads in the cloud, allows customers to focus on the important work they are doing to speed insights and achieve scientific breakthroughs that uncover novel and lifesaving products,” said
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607006006/en/
Media Contact
+1.781.266.2819
naomi.goumillout@agilent.com
Source:
FAQ
What is Agilent Technologies' latest announcement regarding genomic data processing?
How does Agilent Technologies' collaboration with NVIDIA and AWS benefit clinical labs?
What technologies are involved in Agilent's cloud-native analysis platform?
What do Agilent's SureSelect NGS assays offer to researchers?